Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

4049

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines

Interventions

BIOLOGICAL: 31 valent pneumococcal conjugate vaccine
BIOLOGICAL: PCV20
BIOLOGICAL: PCV21

Sponsor

Vaxcyte, Inc.